Aurora Cannabis has launched the English version of its Physician Experience Platform (PEP), designed to give doctors around the world access to real-world case studies on medical marijuana use.
The program is being developed in partnership with Copeia, a German healthcare technology company.
The platform, which first went live in Germany in 2024, now features more than 130 anonymized case reports. Each entry includes patient history, conditions treated, therapeutic outcomes, dosage information and other treatments given alongside marijuana. The goal is to provide physicians with a peer-to-peer educational tool that can help guide prescribing decisions and expand clinical understanding of cannabis-based therapies.
Aurora says the English rollout is a “major milestone” in physician education, opening up access to doctors in Canada, the United Kingdom, Poland, Malta, the Czech Republic, Australia and New Zealand. Copeia’s CEO Garvin Hirt noted that many doctors remain uncertain about prescribing marijuana due to its limited role in formal medical training, and argued that sharing practical case data can help address that gap.
The platform is restricted to verified medical professionals through DocCheck login. While the English version currently allows only read-only access, Aurora and Copeia plan to enable physicians worldwide to contribute their own cases in the future, creating a global database of marijuana-based medical treatments.
Aurora, headquartered in Edmonton, Alberta, is one of Canada’s largest marijuana companies, with operations spanning North America, Europe and Australia. Copeia, founded in 2020, has built a reputation in Germany for its data-driven healthcare platforms and is now expanding globally.
